TDSG.F Stock Overview
A biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.14 |
| 52 Week High | CA$0.24 |
| 52 Week Low | CA$0.076 |
| Beta | 1.19 |
| 11 Month Change | 5.83% |
| 3 Month Change | 56.19% |
| 1 Year Change | -35.63% |
| 33 Year Change | -64.58% |
| 5 Year Change | 11.08% |
| Change since IPO | -95.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| TDSG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.6% | -1.9% | 0.5% |
| 1Y | -35.6% | 10.4% | 20.5% |
Return vs Industry: TDSG.F underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: TDSG.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TDSG.F volatility | |
|---|---|
| TDSG.F Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TDSG.F's share price has been volatile over the past 3 months.
Volatility Over Time: TDSG.F's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides TeloView-SMM application; TeloView, an analysis software platform for prediction of genomic instability. It has a collaboration agreement with the Mayo Clinic to validate its SMM tests for multiple myeloma.
Telo Genomics Corp. Fundamentals Summary
| TDSG.F fundamental statistics | |
|---|---|
| Market cap | US$9.65m |
| Earnings (TTM) | -US$2.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs TDSG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TDSG.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.97m |
| Earnings | -CA$2.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TDSG.F perform over the long term?
See historical performance and comparison